Clinical stage drug development company, Pharmaxis (ASX: PXS) is making a name for themselves in the oncology sector, with their lead asset oncology drug yielding promising results in numerous studies. PXS-5505, a drug designed for the treatment of rare blood cancer myelofibrosis is built on Pharmaxis’ proprietary platform, harnessing the power of enzyme inhibition to
Read More
Our scars tell a story, whether it be grazed knees from the school yard or those mystery scrapes that make you wonder what on earth happened the night before. More often than not these minor scars give us funny stories, laughs and reminders not to touch hot irons. But for more serious injury following events
Read More
Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to realise a $2 million windfall with the sale of their Australian distribution rights, a move that will focus the Company’s efforts towards their advancing cancer treatment clinical trials. The deal will send the distribution rights
Read More